← All trials
NCT06086457
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2023
- Primary completion
- Jun 28, 2026
- Completion date
- Aug 28, 2029
- First posted
- Oct 17, 2023
- Last posted
- Oct 17, 2023
- Enrollment
- 436
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Hebei UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Peking UniversityCollaborator
- Peking UniversityOverall official - principal investigator
- Tengzhou Central People's HospitalCollaborator
- Soochow UniversityCollaborator
- Xiamen UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Henan Medical UniversityCollaborator
- Anyang Regional HospitalCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
- North Sichuan Medical UniversityCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Beijing Cancer Prevention & Treatment SocietyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.